HYAL1 and cancer: In contrast, under-expression of HYAL-1 and HYAL-2 may contribute to poorer prognosis in pancreatic [125], ovarian [126], and endometrial malignancies [127], suggesting that the detrimental effects of hyaluronidases in cancer might vary depending on the type of cancer [128].